Solventum Announces Pricing of its Upsized $2 Billion Note Tender Offers
Rhea-AI Summary
Solventum (NYSE: SOLV) has announced the pricing terms for its upsized note tender offers totaling $2.0 billion in aggregate purchase price. The company is offering to purchase multiple series of outstanding notes across two pools: Pool 1 with a maximum amount of $1.5 billion and Pool 2 with a maximum amount of $500 million.
For Pool 1, Solventum expects to accept approximately $650 million of the 5.450% Senior Notes due 2027 (69.35% proration) and $797.3 million of the 5.400% Senior Notes due 2029 (61.24% proration). In Pool 2, about $457.6 million of the 6.000% Senior Notes due 2064 and $21.9 million of the 5.900% Senior Notes due 2054 will be accepted. Settlement is expected on September 10, 2025.
Positive
- Successful upsizing of tender offers to $2.0 billion demonstrates strong financial capacity
- Strategic debt management through early retirement of higher-interest notes
- High participation rate indicates strong market reception
Negative
- Premium payments required above par value for note repurchases
- Significant cash outlay of $2.0 billion reduces available liquidity
News Market Reaction
On the day this news was published, SOLV gained 2.59%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
The table below sets forth, among other things, the Total Consideration for each series of Notes that is being accepted for purchase, as calculated at 10:00 a.m., Eastern Time, on Sept. 8, 2025.
Title of Security | CUSIPs | Aggregate Principal Amount Outstanding | Maturity Date | Par Call Date1 | Acceptance Priority Level2 | Bloomberg Reference Page | Fixed Spread | Reference Yield | Total Consideration3,4 | Approximate Aggregate Principal Amount Expected | Approximate Proration Factor | ||
Pool 1 Tender Offers | Notes due 2027 | 83444MAN1 83444MAA9 U83448AA5 | Feb. 25, 2027 | Jan. 25, 2027 | 1 | FIT4 | +20 bps | 3.620 % | 69.35 % | ||||
83444MAP6 83444MAC5 U83448AB3 | March 1, 2029 | Feb. 1, 2029 | 2 | FIT1 | +30 bps | 3.564 % | 61.24 % | ||||||
Pool 2 Tender Offers | 83444MAT8 83444MAL5 U83448AF4 | May 15, 2064 | Nov. 15, 2063 | 1 | FIT1 | +100 bps | 4.723 % | N/A | |||||
83444MAS0 83444MAJ0 U83448AE7 | April 30, 2054 | Oct. 30, 2053 | 2 | FIT1 | +85 bps | 4.723 % | 2.58 % |
1 If the repurchase yield as determined in accordance with the Offer to Purchase is less than the contractual annual rate of interest on a particular series of Notes, then the calculation will assume that the payments of such Notes are through the par call date of such Notes; if the repurchase yield as determined in accordance with the Offer to Purchase is higher than or equal to the contractual annual rate of interest on a particular series of Notes, then the calculation will assume that the payments of such Notes are through the maturity date of the Notes of such series.
2 The "Pool 1 Maximum Amount" of
3 Includes an early tender payment of
4 The Total Consideration is calculated using the applicable Fixed Spread for the Notes of such series. The Total Consideration for each series of Notes validly tendered prior to or at 5:00 p.m., Eastern Time, on Sept. 5, 2025 (the "Early Tender Date") and accepted for purchase is inclusive of the applicable early tender payment. The Total Consideration for each series of Notes does not include the applicable accrued interest, which will be payable in addition to the applicable Total Consideration.
Due to the applicable Maximum Amounts, Solventum will not accept for purchase any of the
Notes tendered and not accepted for purchase will be promptly credited to the tendering holder's account or otherwise returned to the holder without cost.
In addition to the applicable Total Consideration for each series of Notes, holders of Notes accepted for purchase will also receive accrued and unpaid interest on Notes validly tendered and accepted for purchase from and including the applicable most recent interest payment date up to but excluding the settlement date, which is currently expected to be Sept. 10, 2025 (the "Settlement Date").
The applicable Total Consideration listed in the table above will be paid per
J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Barclays Capital Inc. and Goldman Sachs & Co. LLC are acting as the lead dealer managers in connection with the Tender Offers (collectively, the "Lead Dealer Managers" and, together with the co-dealer managers named in the Offer to Purchase, the "Dealer Managers"). D.F. King & Co., Inc. is acting as the information and tender agent in connection with the Tender Offers (the "Information and Tender Agent"). Requests for assistance relating to the Tender Offers or for additional copies of the Offer to Purchase or other related documents may be directed to J.P. Morgan Securities LLC at (212) 834-3554 (collect) and (866) 834-4666 (toll free), Morgan Stanley & Co. LLC at (212) 761-1057 (collect) and (800) 624-1808 (toll free), Barclays Capital Inc. at (212) 528-7581 (collect) and (800) 438-3242 (toll free) and Goldman Sachs & Co. LLC at (212) 357-1452 (collect) and (800) 828-3182 (toll free), as the Lead Dealer Managers, or to the Information and Tender Agent at (212) 771-1130 (banks and brokers), (877) 478-5045 (toll free) and SOLV@dfking.com. Holders of the Notes may also contact their broker, dealer, commercial bank, trust company or other nominee or intermediary for assistance concerning the Tender Offers. Holders of the Notes are urged to review the Offer to Purchase for the detailed terms of the Tender Offers and the procedures for tendering their Notes.
Neither the Offer to Purchase nor any related document has been filed with the
This press release does not constitute an offer to purchase, or a solicitation of an offer to sell, or the solicitation of tenders with respect to, the Notes or any other securities. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation, purchase or sale would be unlawful. The Tender Offers are being made solely pursuant to the Offer to Purchase and only to such persons and in such jurisdictions as is permitted under applicable law. None of Solventum or its affiliates, their respective boards of directors, the Dealer Managers, the Information and Tender Agent or the trustee with respect to any series of Notes makes any recommendation as to whether holders of the Notes should tender, or refrain from tendering, all or any portion of the principal amount of their Notes pursuant to the Tender Offers, and no one has been authorized by any of them to make such a recommendation. Holders of the Notes must make their own decision as to whether to tender any of their Notes and, if so, the principal amount of their Notes to tender pursuant to the Tender Offers.
Forward-Looking Statements
This release contains forward-looking statements, including regarding the timing, terms and completion of the Tender Offers. All statements that are not statements of historical fact are forward-looking statements. Such statements are based upon the current beliefs and expectations of Solventum's management and are subject to risks and uncertainties. Actual results could differ materially from those expressed in or implied by the forward-looking statements contained in this release because of a variety of factors, including, but not limited to, general market conditions which might affect the Tender Offers and other factors identified in the Offer to Purchase. For a discussion of such risks and other factors that might impact forward-looking statements, see "Cautionary Note Regarding Forward-Looking Statements" and "Risk Factors" in Solventum's periodic reports on file with the
About Solventum
At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients' lives for the better — while empowering healthcare professionals to perform at their best.
View original content to download multimedia:https://www.prnewswire.com/news-releases/solventum-announces-pricing-of-its-upsized-2-billion-note-tender-offers-302549616.html
SOURCE Solventum